Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
DPP Leader to Urge Drug Price Hikes, “Freeze” on Off-Year Revisions
Yuichiro Tamaki, leader of the Democratic Party for the People (DPP), said on April 16 that he plans to submit an emergency policy proposal to the health minister calling for a “freeze” on off-year drug price revisions and price increases…
To read the full story
Related Article
- DPP Calls for End to Off-Year Drug Price Cuts, Chuikyo Reform
June 15, 2026
- Takaichi Signals Continued Off-Year Revisions despite Abolition Calls
February 26, 2026
- Pharma Fears Off-Year Price Reform Loses Traction after LDP Sweep
February 10, 2026
- Japan Health Minister Says Early Call on FY2027 Off-Year Revision Improves Predictability
January 22, 2026
- Takaichi Pledges Balanced Approach to Drug Pricing, Off-Year Revisions
November 6, 2025
REGULATORY
- Kumamoto Quake Hits 46 Medical Facilities; No Pharma Damage Yet: MHLW
July 29, 2026
- No Cap on FY2027 Budget Requests under Growth Investment Scheme: MOF
July 29, 2026
- Japan Panel Green-Lights GSK’s Hep B Drug, Brinsupri, Hyrnuo
July 28, 2026
- Japanese Women Top Life Expectancy for 41st Year Running
July 28, 2026
- MHLW Sets FY2027 Budget Priorities for Drug Discovery, Advanced Medicine
July 28, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…